• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • Contact

Biovertis AG

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • Contact
biovertis

Biovertis AG

Investment: 2004, Divestment: 2017
Visit Website

Biovertis AG (Vienna, Austria) is a clinical–stage pharmaceutical company. Through its 100% subsidiary Morphochem AG, Biovertis develops small-molecule drugs against multidrug-resistant pathogens.

Morphochem AG (Munich, Germany) is currently developing its proprietary novel Gram-positive antibacterial MCB3837/MCB3681 as an innovative intravenous treatment for Clostridium difficile infection (CDI).

Please see the acquisition announcement here.

 

  • in

Copyright © 2021 · TVM Capital Life Science Venture Capital · Privacy Policy · Contact